Madrid, Spain

Gabriel Simon

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Peter M. Adams, Doug P. Adams, and John Sullivan, Collectively as the Stockholder Representative Committee, Solx, Inc.. Active years: 2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gabriel Simon. Retrieved from https://idiyas.com/inventor/gabriel-simon-h3cxh226

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 


Average Co-Inventor Count = 1.0

ph-index = 2

Forward Citations = 237(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Gabriel Simon: Innovator in Glaucoma Treatment

Introduction

Gabriel Simon is a notable inventor based in Madrid, Spain. He has made significant contributions to the field of ophthalmology, particularly in the treatment of glaucoma. With a total of 2 patents, Simon's work focuses on innovative methods to reduce intraocular pressure and improve patient outcomes.

Latest Patents

Simon’s latest patents include a method for treating glaucoma that involves directing laser light to the ciliary region of the eye. This method stimulates the ciliary region and helps to remove debris that may be obstructing the uveo-scleral outflow pathway. By enhancing aqueous flow from the anterior chamber, this technique effectively reduces intraocular pressure. Another significant patent is an implantable shunt designed to reduce intraocular hypertension. This system features a microchannel with inflow and outflow ports, strategically positioned to optimize its effectiveness when implanted.

Career Highlights

Throughout his career, Gabriel Simon has worked with various organizations, including Solx, Inc. His innovative approaches and dedication to improving glaucoma treatments have positioned him as a key figure in the field.

Collaborations

Simon has collaborated with Peter M. Adams, Doug P. Adams, and John Sullivan, who collectively serve as the Stockholder Representative Committee. Their joint efforts have contributed to advancing the technologies related to glaucoma treatment.

Conclusion

Gabriel Simon's contributions to glaucoma treatment through his innovative patents highlight his commitment to improving patient care. His work continues to influence the field of ophthalmology and offers hope for better management of this challenging condition.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…